NEOGENOMICS INC·4

Jun 3, 7:46 PM ET

Kelly Michael Aaron 4

4 · NEOGENOMICS INC · Filed Jun 3, 2026

Research Summary

AI-generated summary of this filing

Updated

NEOGENOMICS (NEO) Director Kelly Michael Aaron Receives/Exercises Shares

What Happened

  • Director Kelly Michael Aaron reported conversion/exercise and award activity on June 1, 2026. The filing shows conversion/exercise (code M) of 23,077 shares at $0.00, a matching derivative disposal of 23,077 shares at $0.00, and two award/grant entries (code A) for 11,069 and 15,970 shares at $0.00. Gross shares acquired across the entries total 50,116 shares; the filing records a simultaneous disposal of 23,077 shares. All reported transactions have $0 total consideration.

Key Details

  • Transaction date: 2026-06-01; Form 4 filed 2026-06-03 (filed two days after the transactions).
  • Reported prices: $0.00 for all entries; total cash exchanged reported = $0.
  • Shares listed: Acquired = 23,077 (exercise/conversion) + 11,069 (award) + 15,970 (award) = 50,116; Disposed = 23,077.
  • Shares owned after the transactions: not disclosed in the data provided.
  • Footnotes: F1 — reflects release of restricted stock units (RSUs) previously reported on a Form 4. F2 — once vested, the shares of common stock are not subject to expiration.
  • No 10b5-1 plan or late-filing flag noted in the provided data.

Context

  • The entries are derivative-related (exercise/conversion and awards) and reflect issuance/release of previously granted RSUs or similar awards rather than an open-market buy or sale. A same-day "disposed" entry often appears alongside conversions to reflect share surrender/withholding, but the filing itself does not state the reason. These transactions are routine for vesting/settlement of equity awards and do not directly indicate a market-direction trade by the insider.

Insider Transaction Report

Form 4
Period: 2026-06-01
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-06-01+23,07767,086 total
  • Exercise/Conversion

    Restricted Stock Unit

    [F2]
    2026-06-0123,0770 total
    Exercise: $0.00From: 2026-06-01Common Stock (23,077 underlying)
  • Award

    Stock Option (Right to Buy)

    2026-06-01+11,06911,069 total
    Exercise: $10.52From: 2027-06-01Exp: 2036-06-01Common Stock (11,069 underlying)
  • Award

    Restricted Stock Unit

    [F2]
    2026-06-01+15,97015,970 total
    Exercise: $0.00From: 2027-06-01Common Stock (15,970 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    5,000
  • Stock Option (Right to Buy)

    Exercise: $37.53From: 2021-05-28Exp: 2027-05-28Common Stock (2,223 underlying)
    2,223
  • Stock Option (Right to Buy)

    Exercise: $40.90From: 2022-06-02Exp: 2028-06-02Common Stock (3,714 underlying)
    3,714
  • Stock Option (Right to Buy)

    Exercise: $8.10From: 2023-06-10Exp: 2029-06-10Common Stock (13,882 underlying)
    13,882
  • Stock Option (Right to Buy)

    Exercise: $14.82From: 2024-08-10Exp: 2033-08-10Common Stock (8,353 underlying)
    8,353
  • Stock Option (Right to Buy)

    Exercise: $13.71From: 2025-06-01Exp: 2034-06-01Common Stock (8,672 underlying)
    8,672
  • Stock Option (Right to Buy)

    Exercise: $7.28From: 2026-06-01Exp: 2035-06-01Common Stock (16,107 underlying)
    16,107
Footnotes (2)
  • [F1]Reflects release of restricted stock units that were previously reported on a Form 4.
  • [F2]Once vested, the shares of common stock are not subject to expiration.
Signature
/s/ Ali Olivo, Attorney-in-Fact|2026-06-03

Documents

1 file
  • 4
    wk-form4_1780530391.xmlPrimary

    FORM 4